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Summary: This study was designed to evaluate whether Hybrid Capture II (HC2) test
alone refer women to colposcopy as appropriately as DNA Papanicolaou (Pap) test, in
the context of a high-risk group of women using the recently validated DNACitoliq
LBC system. Women with suspected cervical disease were included in this cross-
sectional study at a tertiary center in Sa˜o Paulo, Brazil, for further workup. All women
had cervical material collected for LBC and HC2 for high-risk human papillomavirus
(hrHPV)-DNA test. Irrespective of cytology and HC2 results, colposcopy, and cervical
biopsy when applicable, was systematically performed. All tests were performed
blindly. Sensitivity, specificity, positive and negative predictive values, and overall ac-
curacy of both methods were computed in relation to histology. A total of 1,080 women
were included: 36.4% (393/1080) had ACUS+, 10.2% (110/1080) were high-grade
squamous intraepithelial lesions (HSIL) or cancer. Mean age was 33.5 years. All women
underwent colposcopy, and cervical biopsies were performed in 38.4% (415/1080):
33% (137/415) of the biopsies were negative, 14.4% (155/415) were low-grade squa-
mous intraepithelial lesions (LSIL), 10.7% (116/415) were HSIL, and 0.6% (7/415)
were cancer. HC2 sensitivity to diagnose biopsy-proven HSIL was 100%. Because
all HSIL cases had a positive HC2 test, sensitivity could not be improved by adding
LBC. Specificity and positive and negative predictive values of DNA Pap were not sig-
nificantly different from HC2 test alone when considering LSIL+ histology as ‘‘gold
standard’’ and HSIL+ histology. As a screening strategy for women with high-risk for
cervical cancer, DNA Pap test does not seem to add substantially to HC2 alone in terms
of appropriately referring to colposcopy. KeyWords: Hybrid capture—DCS system—
Liquid-based cytology—Papanicolaou test—Cervical cancer—Cervical screening.
The new century has brought new technologies to
optimize cervical cancer screening. The introduction of
liquid-based cytology (LBC) with preservative liquid me-
dium, allowing for both cell morphology analysis and nu-
cleic acids preservation for molecular tests, has led to
a considerably higher detection rate of high-grade squa-
mous intraepithelial lesions (HSIL) (1,2). Previously, the
Hybrid Capture II (HC2) assay for high- risk human pap-
illomavirus (hrHPV) (Digene Corp., Gaithersburg, MD)
had been approved as a follow-up test for women who
had abnormal or equivocal Papanicolaou (Pap) tests. More
recently, the Food and Drug Administration (3) has granted
approval to the HPV DNA test to be used simultaneously
with LBC Pap test to screen for cervical cancer in women
aged 30 years and older. The American Society of Gynae-
cology also has recommended the use of HC2 for equiv-
ocal cytology (4). Combination of LBC and HC2 for
hrHPV has been reported as a useful technical option
for equivocal diagnoses (5) and to enhance the interval
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of screening (6). The high negative predictive value
(NPV) of HC2 hrHPV-DNA test (HC2) is assumed to be
trustworthy enough to delay the screen interval (5–7). In-
terestingly, the combined LBC primary smear and HPV
testing with a 5-year interval is similar in both cost and
effectiveness to the other 3-yearly options of primary
smear testing or primary HPV testing alone (8). Despite
the recognized success of conventional Pap test in the his-
tory of cervical cancer screening, its limitations, namely
those related to the high false-negative rates, are well known.
Its low sensitivity is a significant problem with public
health implications (9). HPV testing has superior sensi-
tivity than cytology, but lower specificity. Taken together,
combining Pap test and HPV testing seems promising (10).
The use of HPV test as an adjunct technique to improve
cervical screening was first proposed more than a decade
ago (11). Ever since, several purposes to change the or-
thodox prevention organization have been reported to op-
timize the classic system based on the primary screening
with cytology, followed by colposcopy, biopsy, if neces-
sary, and treatment (12). The recently approved DNA Pap
test is a hopeful strategy for cervical cancer screening to
combine the sensitivity of HC2 test and the specificity of
cytology (3). However, is not known whether strategies
that have been shown to be cost-effective to screen the
general population could be safely recommended to screen
special groups of women with high risk for cervical can-
cer or its precursors.
This study was designed to evaluate whether Hybrid
Capture II test alone refer women to colposcopy as ap-
propriately as DNA Pap test, in the context of a high-risk
group of women using the recently validated DNACito-
liq LBC system.
MATERIALS AND METHODS
From January through December 2002, consecutive
women with suspected cervical disease on the grounds
of an abnormal Pap test, and/or altered visual cervical in-
spection were referred for further workup at The Pe´rola
Biygnton Hospital, Sa˜o Paulo, Brazil. All women had
cervical material collected for LBC and HC2 for hrHPV-
DNA test. Irrespective of cytology and HC2 results, col-
poscopy, and cervical biopsy, when applicable, was sys-
tematically performed. LBC, HC2 tests, and histologic
evaluation were processed at the Pathology Division
of Adolfo Lutz Institute. All tests were performed blindly.
The institutional review boards of both institutions in-
volved in the project approved the study protocol.
The brush from the DNA-Citoliq System (DCS;
Digene Brasil, Sa˜o Paulo, Brazil) was used to collect
cervical material, and subsequently placed into tubes
containing 1 ml of the conservative liquid Universal Col-
lection Medium (UCM). Once at the laboratory, batches
of 12 DCS samples were simultaneously prepared in 10 to
15 minutes. In that system, the specimen in the slide is
contained in a 25-mm-diameter circle. Cytology results
were reported using the terminology of the Bethesda
2001 System (13), with the exception that atypical squa-
mous (ASC-US) and glandular (AGC) cells of undeter-
mined significance were grouped in one variable referred
to as ACUS.
HC2 test was performed according to the instructions
of the manufacturer. Only the probe for high-risk HPV
was used.
Histologic specimens were initially evaluated accord-
ing to WHO classification of squamous lesions in three
classes (CIN 1, 2, and 3) (14). However, for the purposes
of statistical analyzes, results were presented in two cat-
egories: low-grade squamous intraepithelial lesions (LSIL)
(CIN 1) and HSIL (CIN 2 and 3).
Statistical Analysis
Sensitivity, specificity, positive (PPV), and negative
(NPV) predictive values of HC2, LBC, and DNA Pap
in diagnosing women with cervical disease were calcu-
lated having both HSIL+ and LSIL+ histologic results
as ‘‘gold standard.’’ The cutoff for a positive LBC was
ACUS or higher (ACUS+). HC2 was deemed positive
if the relative light units (RLU) were 1 or greater. The
McNemar chi-square test was used to test for statistical
differences in diagnostic parameters of the three screen-
ing strategies. Impact on diagnostic parameters of chang-
ing histologic cutoff from LSIL to HSIL was assessed by
the chi-square test. A difference was statistically signif-
icant if p < 0.05. Data were stored and analyzed using
the SPSS statistical software, version 10.1 (SPSS Inc.,
Chicago, IL).
RESULTS
Of 1,095 women included in the study, 15 had unsat-
isfactory LBC preparation and were excluded. Among
the remaining 1,080 women, 36.4% (393/1080) had a
LBC showing ACUS+, 10.2% (110/1080) being HSIL
or cancer. Mean age was 33.5 (range, 16–73) years. All
women underwent colposcopy, and cervical biopsies
were performed in 38.4% (415/1,080). Thirty-three per-
cent (137/415) of those biopsies were negative, 14.4%
(155/415) were LSIL, 10.7% (116/415) were HSIL, and
0.6% (7/415) were cancer.
39DNA PAP TEST IN HIGH-RISK POPULATION
Int J Gynecol Pathol, Vol. 25, No. 1, January 2006
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
The diagnostic parameters of HC2, LBC, and com-
bined HC2 and LBC (DNA Pap) in relation to histology
are shown in Table 1. HC2 sensitivity to diagnose biopsy-
proven HSIL was 100%, whereas it declined to 84.2%
in case the definition of a positive histologic result was
downgraded to LSIL+ (p< 0.0001). In contrast, there
is an increment on HC2 specificity when the histologic
definition switches from HSIL+ (42.8%) to LSIL+
(59.1%) (p = 0.002). The same pattern is observed with
LBC and DNA Pap.
To assess the diagnostic contribution of LBC in this
high-risk population, sensitivity, specificity, and predic-
tive values of DNA Pap were compared with same diag-
nostic parameters of HC2 test alone (Tables 2 and 3).
Because all HSIL cases had a positive HC2 test, sensitiv-
ity could not be improved by adding LBC. Specificity and
positive and negative predictive values of DNA Pap were
not significantly different from HC2 test alone when con-
sidering LSIL+ histology as ‘‘gold standard’’ and HSIL+
histology.
Sensitivity and NPV when diagnosing HSIL+ his-
tology were significantly higher for HC2 test than for
LBC, whereas LBC had greater specificity and PPV
(Table 2). For LSIL histology, HC2 test and LBC had
similar predictive values (Table 3).
DISCUSSION
In the present investigation of high-risk women for cer-
vical cancer and its precursors, the diagnostic performance
of HC2 test alone to detect HSIL+ was similar to com-
bined LBC and HC2 test (DNA Pap). All histologically
proven HSIL+ were detected by HC2 and DNA Pap, as
opposed to nine cases missed by LBC. Furthermore,
specificity, PPV, and NPV for HC2 test and DNA Pap
were not statistically different. The definition of a positive
histologic result (LSIL+ or HSIL+) greatly influences the
diagnostic parameters of the three screening strategies.
Similarly, if DNA Pap is computed as positive only when
both HC2 and LBC are positive also will significantly in-
fluence diagnostic parameters of the tests.
In the present study, DNA Pap was computed as pos-
itive when HC2 or LBC were positive. All remaining
combinations of the two screening tests were computed
as a negative DNA Pap. Such definitions prioritize sen-
sitivity at the expense of specificity. Indeed, the observed
100% sensitivity of DNA Pap for detecting HSIL+ would
have significantly decreased to 92.7% (p< 0.0001) had
the definition of a positive DNA Pap been both HC2 test
and LBC positive.
In this group of high-risk women for cervical cancer
included in this study, adding LBC to HC2 test did not
add in terms of subsequent patient management. In fact,
considering HSIL+ or LSIL+ as ‘‘gold standard,’’ the sen-
sitivity, specificity, and predictive values of HC2 alone
and DNA Pap test did differ significantly (Tables 2
and 3). This finding is in sharp contrast to what has been
TABLE 1. Diagnostic performance of HC2, LBC, and






Sensitivity 234/278 (84.2) 123/123 (100) <0.0001
False-positive 56/137 (40.9) 167/292 (57.2) 0.002
False-negative 44/280 (15.8) 0/123 (0) <0.0001
Specificity 81/136 (59.1) 125/292 (42.8) 0.002
LBC ACUS+
Sensitivity 195/278 (70.1) 114/123 (92.7) <0.0001
False-positive 38/137 (27.7) 119/292 (40.8) 0.01
False-negative 83/278 (29.9) 9/123 (7.3) <0.0001
Specificity 99/137 (72.3) 173/292 (59.2) 0.01
DNA Pap
Sensitivity 239/278 (86) 123/123 (100) <0.0001
False-positive 66/137 (48.2) 182/292 (62.3) 0.008
False-negative 39/278 (14) 0/123 (0) <0.0001
Specificity 71/137 (51.8) 110/292 (37.7) 0.008
LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade
squamous intraepithelial lesions; HC2, Hybrid Capture II. Data are
numbers with percentages in parentheses.
TABLE 2. Efficiency of HC2, cervical cytology (ASCUS+),
and DNA PAP+(HCII or ASCUS+) to diagnose histologically
confirmed cervical high-grade lesions (HSIL) or cancer
HC2 ASCUS+ p value* DNA PAP† p value‡
Sensiytivity 100% 92.7% 0.007 100% 1
Specificity 42.8% 59.2% 0.0001 37.7% 0.23
PPV 42.4% 48.9% 0.16 41.7% 0.36
NPV 100% 95.1% 0.03 100% 0.28
PPV, positive predictive value; NPV, negative predictive value.
* HC2 versus LBC comparison.
† Positive HC2 or the presence of ASCUS+ considered a positive test.
‡ HC2 versus DNA PAP comparison.
TABLE 3. Efficiency of HC2, cervical cytology (ASCUS+),
and DNA PAP+(HCII or ASCUS+) to diagnose histologically
confirmed cervical low-grade lesions (LSIL), HSIL, or cancer
HC2 ASCUS+ p value* DNA PAP† p value‡
Sensitivity 84.2% 70.1% 0.0001 86% 0.63
Specificity 59.1% 72.3% 0.03 51.8% 0.27
PPV 80.7% 83.7% 0.44 78.4% 0.55
NPV 64.8% 54.4% 0.09 64.5% 0.92
PPV, positive predictive value; NPV, negative predictive value.
* HC2 versus LBC comparison.
† Positive HCII or the presence of ASCUS+ considered a positive test.
‡ HC2 versus DNA PAP comparison.
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observed in the general population, in which the preva-
lence of HSIL is far lower than the 10.2% encountered
in our study. Thus, in the general population of women,
screening programs based on primary HPV testing and
combined HPV and LBC would give rise to a far greater
risk of inappropriate referral to colposcopy, as result of
high proportion of false-positive tests (8). However, in
groups of women with high prevalence of cervical dis-
ease, 40.9% of the women with no cervical lesions would
be referred to colposcopy on the grounds of a positive
HC2 alone, whereas 48.2% would be referred based on
a LBC showing ASC-US+ (McNemar test: p< 0.002),
or 13.7% more inappropriate referral with DNA Pap.
At this high disease prevalence level, despite having su-
perior specificity, LBC missed 7.3% of HSIL, as opposed
to HC2, which detected all cases.
On the other hand, because all cases with HSIL would
have been appropriately referred to colposcopy by HC2
test alone, adding LBC would be of no benefit. Similarly,
a negative HC2 test alone would fail to appropriately re-
fer 15.8% of women with LSIL, whereas DNA Pap would
not refer 14% of those women (McNemar test: p = 0.06).
The histologic cutoff chosen as ‘‘gold standard,’’ LSIL+
or HSIL+, has a clear impact on the diagnostic parameters
of the screening tests being assessed (Table 1). Sensitivity
increases when HSIL is the cutoff and consequently spec-
ificity will decrease. Which cutoff to choose will depend on
the goal set for the screening program that is being eval-
uated. A possible objective could be to detect all HSIL,
whereas a more comprehensive goal would be the detec-
tion of all lesions. In that case, the cutoff should be LSIL+.
In conclusion, as a screening strategy for women with
high-risk for cervical cancer, DNA Pap test does not seem
to add substantially to HC2 alone in terms of appropri-
ately referring to colposcopy.
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